Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. The understanding of the checkpoint signalling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) in tumour-induced immune suppression has been a critical advancement in immunotherapeutic drug development.
Cell signalling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and is exploited by both tumours and viruses. The PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signalling. The kit comes in a convenient 96-well format, with biotin-labelled PD-1, purified PD-L1 or PD-L2, streptavidin labelled HRP, and assay buffer for 100 binding reactions. The key to the kit is the high sensitivity of detection of biotin-labelled PD-1 by streptavidin-HRP. Only a few simple steps on a microplate are required for the assay. AMSBIO
Print this page